Cell Line, Tumor
"Cell Line, Tumor" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A cell line derived from cultured tumor cells.
| Descriptor ID |
D045744
|
| MeSH Number(s) |
A11.251.210.190 A11.251.860.180
|
| Concept/Terms |
Cell Line, Tumor- Cell Line, Tumor
- Cell Lines, Tumor
- Line, Tumor Cell
- Lines, Tumor Cell
- Tumor Cell Lines
- Tumor Cell Line
|
Below are MeSH descriptors whose meaning is more general than "Cell Line, Tumor".
Below are MeSH descriptors whose meaning is more specific than "Cell Line, Tumor".
This graph shows the total number of publications written about "Cell Line, Tumor" by people in this website by year, and whether "Cell Line, Tumor" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2000 | 0 | 1 | 1 | | 2002 | 0 | 1 | 1 | | 2003 | 2 | 19 | 21 | | 2004 | 0 | 46 | 46 | | 2005 | 0 | 57 | 57 | | 2006 | 0 | 74 | 74 | | 2007 | 1 | 63 | 64 | | 2008 | 0 | 74 | 74 | | 2009 | 0 | 90 | 90 | | 2010 | 2 | 92 | 94 | | 2011 | 1 | 114 | 115 | | 2012 | 0 | 106 | 106 | | 2013 | 1 | 118 | 119 | | 2014 | 1 | 105 | 106 | | 2015 | 1 | 123 | 124 | | 2016 | 0 | 109 | 109 | | 2017 | 2 | 132 | 134 | | 2018 | 0 | 138 | 138 | | 2019 | 0 | 113 | 113 | | 2020 | 1 | 72 | 73 | | 2021 | 0 | 82 | 82 | | 2022 | 0 | 42 | 42 | | 2023 | 0 | 40 | 40 | | 2024 | 0 | 106 | 106 | | 2025 | 0 | 132 | 132 | | 2026 | 0 | 67 | 67 |
To return to the timeline, click here.
Below are the most recent publications written about "Cell Line, Tumor" by people in Profiles.
-
Ota Y, Elizagaray ML, Gupta V, Fashemi BE, Akande M, Babu P, Thuthika PK, Lomonosova E, Brill J, Sun L, Sanders B, Kuroki LM, McCourt CK, Hagemann AR, Hagemann IS, Thaker PH, Mutch DG, Powell MA, Hyrc K, Verma P, Krais J, Bitler BG, Mullen MM, Khabele D. RAD52 is a therapeutic vulnerability for acquired PARP inhibitor resistance in ovarian cancer. JCI Insight. 2026 Nov 09; 11(21).
-
López-Hernández L, Crowley SJ, Cea-Sánchez S, de Arellano R, Krishnan N, Toolan-Kerr P, White L, Ignoti D, Soto-Hidalgo E, Gustincich S, González-Prieto R, Pandolfini L, Barbieri I, Altea-Manzano P, Magee JA, Ferraro F, Taylor SJ, Bednarski JJ, Millán-Zambrano G. BCLAF1 links RNA splicing to ATF4-dependent metabolic adaptation in acute myeloid leukemia. Sci Adv. 2026 Nov 06; 12(45):eaeg0571.
-
Martinez A, Pearson CG. Centriolar satellites regulate CEP350 mRNA stability and centrosome amplification. Mol Biol Cell. 2026 Oct; 37(10):br31.
-
Kim A, Bhardwaj P, Rehman S, Zhao SJ, Lucas KN, Noronha KJ, Bhatt D, Friedman S, Morotti R, Sundaram RK, Dela Cruz FS, Feinberg TY, Ramakrishnan S, Xue W, Barkauskas DA, Hall D, Shern JF, Sun W, Barr FG, Yi JS, Spurrier J, Yu A, Brenner C, Heer CD, Heske CM, Vasquez JC. NAPRT Expression and Epigenetic Regulation in Pediatric Rhabdomyosarcoma as a Potential Biomarker for NAMPT Inhibition. Mol Cancer Ther. 2026 Oct 02; 25(10):1771-1784.
-
Cheng K, Nie H, Zhou W, Guo D, Liao L, Zhang X, Wang C, Zielinski RJ, Gavade JN, Sriramkumar S, Fang Y, Xia S, Wu S, Tang HY, Kossenkov AV, Qi Y, Liu J, Le K, Gruber D, Soth MJ, Post MD, Sood AK, Flückiger-Mangual S, Yap TA, Bitler BG, Zhang R. Targeting p300 Reverses Acidic Microenvironment-Induced PARP Inhibitor Resistance. Cancer Res. 2026 Oct 02; 86(19):4934-4954.
-
Bower BM, Ho GM, Saemundsson SA, Goodwin AP, Cha JN. Optimization of Affibody Affinity to Improve Distribution in Tumor Models. Biomacromolecules. 2026 Sep 14; 27(9):6134-6142.
-
Kar A, Banerjee T, Pozdeyev N, Holmstoen TB, Foust LJ, Bagby SM, Pitts TM, Habra MA, Wierman ME, Kiseljak-Vassiliades K. Comprehensive profiling of OTSSP167 action in adrenocortical carcinoma. Endocrinology. 2026 Sep 03; 167(10).
-
Gaikwad H, Angarita D, Carter N, Reichardt N, Siegel D, Mattanovich H, De Melo DM, Anchordoquy TJ, Aguado J, Graner A, Graner M, Balyasnikova IV, Simberg D. Physicochemical and molecular determinants of lipid migration through multicellular assemblies. J Control Release. 2026 Nov 10; 399(Pt A):115326.
-
Mikeska RG, Feldman LER, Woodruff ER, Iwanaga R, Linder KE, Yamamoto TM, Sompel K, Jordan KR, Post MD, Zoller M, Bitler BG, Marjon NA. Inhibiting CXCR2 Remodels the Tumor Microenvironment and Blunts Tumor Progression and Dissemination of High-Grade Serous Carcinoma. Cancer Res Commun. 2026 Sep 01; 6(9):2256-2270.
-
Gilchrist DE, Thompson KN, Ju JA, Annis DA, Mull ML, Omili DO, Cornell JL, Dimitrova N, Hendrick H, Yu M, Schmitz JC, Owonikoko TK, Vitolo MI, Martin SS. Single-Cell Profiling of Apoptotic Resistance in Patient-Derived Xenografts and Primary Circulating Tumor Cells Using TetherChip. ACS Appl Mater Interfaces. 2026 Aug 26; 18(33):44874-44888.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|